China-based Hangzhou HealZen Therapeutics Co., Ltd., in collaboration with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (SIMM), has entered into a global license deal with US pharmaceutical giant Johnson & Johnson (J&J, NYSE: JNJ). The partnership aims to develop potential best-in-class BTK degraders for the treatment of multiple diseases. Financial details of the agreement were not disclosed.
HealZen’s DaTProD Platform and Pipeline
HealZen, a leading small molecule drug developer, is known for its proprietary DaTProD platform. This innovative platform leverages omics and AI technology to develop targeted protein degraders (TPDs) with differentiated advantages. The company is currently developing a PROTAC molecule, HZ-Q1070, which is a BTK degrader targeting hematoma and autoimmune diseases. HZ-Q1070 is currently in Phase I clinical trials, demonstrating HealZen’s commitment to advancing novel therapeutics in the field of protein degradation.
Future Prospects
The global license deal with Johnson & Johnson is a significant milestone for HealZen, providing the company with the resources and expertise to accelerate the development of its BTK degrader program. By partnering with a global leader like Johnson & Johnson, HealZen aims to bring innovative treatments to patients suffering from a range of diseases, leveraging the potential of BTK degradation technology. This collaboration underscores the growing interest in targeted protein degradation as a therapeutic strategy and positions HealZen at the forefront of this emerging field.-Fineline Info & Tech
Leave a Reply